Orion Capital Management LLC Buys Shares of 1,524 Edwards Lifesciences Co. (NYSE:EW)

Orion Capital Management LLC purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,524 shares of the medical research company’s stock, valued at approximately $113,000.

Several other institutional investors have also modified their holdings of EW. Crowley Wealth Management Inc. acquired a new stake in Edwards Lifesciences during the 4th quarter worth approximately $26,000. Millstone Evans Group LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $30,000. Catalyst Capital Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $54,000. Finally, SBI Securities Co. Ltd. bought a new stake in Edwards Lifesciences in the 4th quarter valued at $62,000. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on EW. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Evercore ISI dropped their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. Truist Financial reduced their price target on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating for the company in a research report on Friday, April 11th. Robert W. Baird boosted their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a “neutral” rating in a research report on Thursday, April 24th. Finally, Barclays raised their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $79.60.

Edwards Lifesciences Stock Performance

NYSE EW opened at $77.82 on Wednesday. The stock has a market cap of $45.65 billion, a PE ratio of 11.16, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a 50-day moving average of $72.47 and a 200-day moving average of $71.90. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.25.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm had revenue of $1.41 billion for the quarter, compared to analysts’ expectations of $1.40 billion. During the same period in the prior year, the firm earned $0.66 EPS. The business’s revenue was up 6.2% on a year-over-year basis. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling

In related news, CEO Bernard J. Zovighian sold 6,164 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the sale, the chief executive officer now directly owns 59,083 shares in the company, valued at approximately $4,106,859.33. The trade was a 9.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $70.78, for a total value of $796,275.00. Following the sale, the chief financial officer now directly owns 30,387 shares in the company, valued at $2,150,791.86. This represents a 27.02% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 66,192 shares of company stock valued at $4,709,454. Insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.